1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY


3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Drug Delivery Systems
3.3. Drawbacks of Conventional Parenteral Delivery Systems
3.4. Needlestick Injuries
3.4.1. Incidence and Cost Burden
3.4.2. Government Legislation for the Prevention of Needlestick Injuries
3.5. Emerging Trend of Self-Administration
3.5.1. Rising Burden of Chronic Diseases
3.5.2. Healthcare Cost Savings
3.5.3. Need for Immediate Treatment in Emergency Situations
3.5.4. Growth of Injectable Biologics Market
3.5.5. Addressing Key User Safety Requirements
3.6. Types of Self-administration Devices
3.6.1. Prefilled Syringes
3.6.2. Pen-Injectors
3.6.3. Needle-Free Injectors
3.6.4. Autoinjectors
3.6.5. Large Volume Wearable Injectors
3.7. Overview of Autoinjectors
3.7.1. Components of Autoinjectors
3.7.2. Classification of Autoinjectors
3.7.2.1. On the Basis of Mechanism of Action
3.7.2.2. On the Basis of Usability
3.7.2.3. On the Basis of Type of Dose
3.7.3. Manufacturing / Packaging of Autoinjectors
3.7.4. Benefits of Autoinjectors
3.8. Regulatory Considerations
3.8.1. Medical Devices
3.8.2. Drug Device Combination Products
3.9. Future Perspectives


4. PRIMARY DRUG CONTAINERS
4.1. Chapter Overview
4.2. Types of Packaging
4.3. Introduction to Primary Drug Containers
4.3.1. Role of Primary Drug Containers
4.3.2. Types of Primary Drug Containers
4.3.2.1. Cartridges
4.3.2.1.1. Components of Cartridges
4.3.2.1.2. Types of Cartridges
4.3.2.1.2.1. Single Chamber Cartridge
4.3.2.1.2.2. Dual Chamber Cartridge
4.3.2.1.3. Cartridges Available in the Market
4.3.2.2. Syringes
4.3.2.2.1. Components
4.3.2.2.2. Types of Syringes
4.3.2.2.2.1. Based on Number of Chambers
4.3.2.2.2.2. Based on Type of Needle
4.3.2.2.3. Prefilled Syringe Systems Available in the Market
4.3.2.2.3.1. Glass Prefilled Syringes
4.3.2.2.3.2. Plastic Prefilled Syringes
4.3.2.3. Vials
4.3.2.3.1. Components
4.3.2.3.2. Vials Available in the Market
4.4. Comparison of Fabrication Materials


5. AUTOINJECTORS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Autoinjectors: Overall Market Landscape
5.2.1. Analysis by Usability
5.2.2. Analysis by Type of Primary Container
5.2.3. Analysis by Volume of Container
5.2.4. Analysis by Dosage Type
5.2.5. Analysis by Route of Administration
5.2.6. Analysis by Actuation Mechanism
5.2.7. Analysis by Type of Feedback Mechanism
5.3. Autoinjectors: Developer Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Geographical Location of Headquarters


6. PRODUCT COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Assumptions and Key Parameters
6.4. Product Competitiveness Analysis: Disposable Autoinjectors
6.5. Product Competitiveness Analysis: Reusable Autoinjectors


7. BRAND POSITIONING ANALYSIS OF KEY INDUSTRY PLAYERS
7.1 Chapter Overview
7.2. Scope and Methodology
7.3. Brand Positioning Matrix: Company 1
7.4. Brand Positioning Matrix: Company 2
7.5. Brand Positioning Matrix: Company 3
7.6. Brand Positioning Matrix: Company 4
7.7. Brand Positioning Matrix: Company 5
7.8. Brand Positioning Matrix: Company 6
7.9. Brand Positioning Matrix: Company 7
7.10. Brand Positioning Matrix: Company 8
7.11. Brand Positioning Matrix: Company 9
7.12. Brand Positioning Matrix: Company 10
7.13. Brand Positioning Matrix: Company 11
7.14. Brand Positioning Matrix: Company 12


8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Autoinjectors: Patent Analysis
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Geography
8.3.3. Analysis by CPC Symbols
8.3.4. Emerging Focus Areas
8.3.5. Analysis by Type of Organization
8.3.6. Leading Players: Analysis by Number of Patents
8.4. Autoinjectors: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.5. Autoinjectors: Patent Valuation Analysis


9. THERAPEUTIC PRODUCTS AVAILABLE IN AUTOINJECTORS
9.1. Chapter Overview
9.2. Autoinjector Combination Products: List of Approved Drugs
9.2.1. Analysis by Initial Year of Approval
9.2.2. Analysis by Usability
9.2.3. Analysis by Route of Administration
9.2.4. Analysis by Primary Drug Container
9.2.5. Analysis by Type of Molecule
9.2.6. Analysis by Dose Strength
9.2.7. Analysis by Therapeutic Indication
9.2.8. Analysis by Other Packaging Formats of Marketed Drugs
9.3. Autoinjector Combination Products: List of Pipeline Drugs
9.3.1. Analysis by Phase of Development
9.3.2. Analysis by Route of Administration
9.3.3. Analysis by Type of Molecule
9.3.4. Analysis by Therapeutic Indication
9.3.5. Grid Analysis: Distribution by Therapeutic Indication, Phase of Development and Route of Administration
9.4. Autoinjector Combination Products: List of Developers
9.4.1. Analysis by Year of Establishment
9.4.2. Analysis by Company Size
9.4.3. Analysis by Location of Headquarters


10. CASE STUDY: AUTOINJECTOR-BASED COMBINATION PRODUCTS AND AFFILIATED THERAPEUTIC AREAS
10.1. Chapter Overview
10.2. Marketed / Pipeline Autoinjector-based Combination Products
10.3. Case Study on Anaphylaxis
10.3.1. Overview and Epidemiology
10.3.2. Adrenaline: Mechanism of Action
10.3.3. History of Development
10.3.4. Marketed Adrenaline / Epinephrine Autoinjectors
10.3.4.1. Adrenaclick
10.3.4.2. Allerject / Auvi-Q (Formerly called e-cue)
10.3.4.3. Anapen
10.3.4.4. Emerade
10.3.4.5. EpiPen / EpiPen Jr
10.3.4.6. Jext
10.3.4.7. EpiPen / EpiPen Jr
10.3.5. Adrenaline / Epinephrine Autoinjectors Under Development
10.3.5.1. EpiQ
10.3.5.2. ANDIPen
10.3.5.3. MiniEpi
10.3.5.4. Zeneo Adrenaline
10.3.6. Other Dosage Forms
10.3.7. Historical Sales of Approved Drugs / Autoinjectors

10.4. Case Study II: Multiple Sclerosis
10.4.1. Overview and Epidemiology
10.4.2. Interferon ?-1a
10.4.3. Interferon ?-1b
10.4.4. Interferons: Mechanism of Action
10.4.5. History of Development
10.4.6. Interferon ?-1a Autoinjectors
10.4.6.1. Avonex Pen
10.4.6.2. PLEGRIDY Pen
10.4.6.3. Rebif Rebidose
10.4.6.4. RebiSmart
10.4.6.5. Rebiject II
10.4.6.6. ReciGen Physioject
10.4.7. Interferon ?-1b Autoinjectors
10.4.7.1. BETACONNECT
10.4.7.2. BETAJECT Comfort / Betacomfort
10.4.7.3. Betaject Lite
10.4.7.4. ExtaviJect 30G / ExtaviPro 30G
10.4.8. Other Marketed Autoinjectors
10.4.8.1. Cinnomer40 Physioject
10.4.8.2. CSYNC Autoinjector
10.4.8.3. WhisperJECT
10.4.8.4. Remurel Autoxon
10.4.9. Other Dosage Forms
10.4.10. Historical Sales of Approved Drugs / Autoinjectors
10.4.10.1. Interferon ?-1a
10.4.10.2. Interferon ?-1b
10.5. Case Study III: Migraine
10.5.1. Overview and Epidemiology
10.5.2. Sumatriptan Succinate: Mechanism of Action
10.5.3. History of Development
10.5.4. Marketed Autoinjectors
10.5.4.1. ALSUMA
10.5.4.2. IMITREX STATdose Pen
10.5.4.3. Zembrace SymTouch
10.5.4.4. Aimovig SureClick Autoinjector
10.5.4.5. Emgality Prefilled Pen
10.5.5. Other Dosage Forms
10.5.6. Historical Sales of Approved Drugs / Autoinjectors

10.6. Case Study IV: Rheumatoid Arthritis
10.6.1. Overview and Epidemiology
10.6.2. History of Development
10.6.3. Marketed Autoinjectors for Rheumatoid Arthritis
10.6.3.1. Actemra
10.6.3.2. CIMZIA AutoClicks Prefilled Pen
10.6.3.3. Enbrel SureClick
10.6.3.4. Hulio Prefilled Pen
10.6.3.5. HUMIRA Pen
10.6.3.6. ORENCIA ClickJect
10.6.3.7. OTREXUP
10.6.3.8. Rasuvo Autoinjector
10.6.3.9. SIMPONI SmartJect Autoinjector
10.6.3.10. KEVZARA Prefilled Pen
10.6.3.11. IMRALDI Prefilled Pen
10.6.4. Historical Sales of Approved Drugs / Autoinjectors


11. LIKELY DRUG CANDIDATES FOR DELIVERY VIA AUTOINJECTORS
11.1. Chapter Overview
11.2. Methodology and Key Parameters
11.3. Marketed Drug Candidates for Delivery via Autoinjectors
11.3.1. Most Likely Drug Candidates
11.3.2. Likely Drug Candidates
11.3.3. Less Likely Drug Candidates
11.3.4. Unlikely Drug Candidates
11.4. Clinical Drug Candidates for Delivery via Autoinjectors
11.4.1. Most Likely Drug Candidates
11.4.2. Likely Drug Candidates
11.4.3. Less Likely Drug Candidates
11.4.4. Unlikely Drug Candidates

12. COMPANY PROFILES
12.1. Chapter Overview
12.2. Antares Pharma
12.2.1. Company Overview
12.2.2. Financial Information
12.2.3. Product Portfolio
12.2.3.1. Autoinjectors: Product Details
12.2.3.1.1. Vibex
12.2.3.1.2. QuickShot
12.2.3.1.3. BigShot
12.2.4. Collaborations
12.2.4.1. Teva Pharmaceutical
12.2.4.2. Ferring Pharmaceuticals
12.2.4.3. AMAG Pharmaceuticals
12.2.4.4. JCR Pharmaceuticals
12.2.4.5. Pfizer
12.2.4.6. Idorsia Pharmaceuticals
12.2.4.7. Lunatus Global Medical Supplies
12.2.5. Recent Developments and Future Outlook
12.3 Bespak (Acquired by Recipharm)
12.3.1. Company Overview
12.3.2. Financial Information
12.3.3. Technology Overview
12.3.4. Product Portfolio
12.3.4.1. Autoinjectors: Product Details
12.3.4.1.1. Syrina
12.3.4.1.2. OTS Autoinjector
12.3.4.1.3. Viscala Autoinjector
12.3.5. Collaborations
12.3.5.1. Undisclosed Global Biopharmaceutical Company
12.3.5.2. Regeneron Pharmaceuticals
12.3.6. Recent Developments and Future Outlook
12.4. DALI Medical Devices
12.4.1. Company Overview
12.4.2. Product Portfolio
12.4.2.1. Autoinjectors: Product Details
12.4.2.1.1. SAN-L
12.4.2.1.2. SAN-P
12.4.2.1.3. SAN-DV
12.4.2.1.4. SAN-DV Pro
12.2.2.1.5. SAN-Light
12.4.3. Collaborations
12.4.3.1. Elcam Drug Delivery Devices
12.4.4. Recent Developments and Future Outlook
12.5. Elcam Medical (E3D Elcam Drug Delivery Devices)
12.5.1. Company Overview
12.5.2. Product Portfolio
12.5.2.1. Autoinjectors: Product Details
12.5.2.1.1. Flexi-Q Disposable Autoinjectors
12.5.2.1.1.1. Flexi-Q PFS
12.5.2.1.1.2. Flexi-Q HV
12.5.2.1.1.3. Flexi -Q DV
12.5.2.1.1.4. Flexi-Q EAI
12.5.2.1.1.5. Flexi-Q CAI
12.5.2.1.2. Flexi-Q Reusable Autoinjectors
12.5.2.1.2.1. Flexi-Q mMU
12.5.2.1.2.2. Flexi-Q eMU-C / P
12.5.3. Comparison of Elcam Medical Autoinjectors
12.5.4. Collaborations
12.5.4.1. DALI Medical Devices
12.5.4.2. Jabil Healthcare
12.5.5. Recent Developments and Future Outlook
12.6. Jiangsu Delfu Medical Devices
12.6.1. Company Overview
12.6.2. Product Portfolio
12.6.2.1. Autoinjectors: Overview and Specifications
12.6.2.1.1. Components of Delfu Autoinjectors
12.6.2.1.2. Applications of Delfu Autoinjectors
12.6.2.1.3. Features of Delfu Autoinjectors
12.6.2.1.4. Advantages of Delfu Autoinjectors
12.6.2.1.5. Specifications of Delfu Autoinjectors
12.6.2.2. Autoinjectors: Product Details
12.6.2.2.1. YZ-II 3mL Cartridge Digital Dose Setting GF Autoinjector
12.6.2.2.2. DZ-IA 3 mL Cartridge Needle Hidden Vaccination Autoinjector
12.6.2.2.3. DZ-IA Auto Injector Pen
12.6.2.2.4. DZ-IA 3mL*0.1u Needle Hidden Smart VEGF Injection Pen
12.6.2.2.5. YZ-III Standard 3 mL Cartridge Reusable Electronic Auto Injector Pen
12.6.3.2.6. YZ-III 0.001mL Dose Increments Fully Automated Reusable Injectors
12.6.3.2.7. YZ-III 0.001 mL Dose Accuracy Auto Injector Pen
12.6.3.2.8. YZ-II 3mL* 1u Auto Injector Pen
12.6.3.2.9. YZ-V 3 mL Cartridge Replaceable Variable-dose Classic Auto Injector Pen
12.6.3.2.10. YZ-III Automatic Reusable Insulin Injection Pen
12.6.4. Recent Developments and Future Outlook
12.7. Oval Medical Technologies
12.7.1. Company Overview
12.7.2. Product Portfolio
12.7.2.1. Autoinjectors: Product Details
12.7.2.1.1 ArQ
12.7.2.1.2 ArQ-Bios
12.7.2.1.3 ArQ-Tempo
12.7.2.1.4 ArQ-Vita
12.7.3. Collaborations
12.7.3.1. SOLIZE
12.7.4. Recent Developments and Future Outlook
12.8. Owen Mumford
12.8.1. Company Overview
12.8.2. Product Portfolio
12.8.2.1. Autoinjectors: Product Details
12.8.2.1.1. Autoject Micro
12.8.2.1.2. Autoject 2
12.8.2.1.3. Autoject Mini
12.8.2.1.4. Autoject Visco
12.8.2.1.5. Autoject Uni
12.8.2.1.6. Autoject Multi
12.8.2.1.7. Autoject Flex
12.8.2.1.8. UniSafe Auto-injector
12.8.2.1.9. UniSafe Connected Auto-injector
12.8.3. Collaborations
12.8.3.1. Nipro
12.8.3.2. Sanofi Aventis
12.8.4. Recent Developments and Future Outlook
12.9. SHL Group
12.9.1. Company Overview
12.9.2. Product Portfolio
12.9.2.1. Two-Step Disposable Autoinjectors: Product Details
12.9.2.1.1 Amber (Pushclick Technology)
12.9.2.1.2. Molly
12.9.2.1.3. Molly RNS
12.9.2.1.4. Molly 2.25
12.9.2.1.5. Rotaject
12.9.2.1.6. Bertha
12.9.2.1.7. DAI 2
12.9.2.1.8. Maggie
12.9.2.1.9. Comparison of SHL Two-Step Autoinjectors
12.9.2.2. Three-Step Disposable Autoinjectors: Product Details
12.9.2.2.1. DAI
12.9.2.2.2. SDI-MIX+NIT (Needle Isolation Technology and Twist and Mix Mechanism)
12.9.2.2.3. VSDI+NIT
12.9.2.2.4. Comparison of SHL Three-Step Autoinjectors
12.9.2.3. PPI Injector (Rotaject Pressure Release Technology)
12.9.2.4. PenInject2.25
12.9.4. Collaborations
12.9.4.1. Schreiner MediPharm
12.9.4.2. QuiO
12.9.5. Recent Developments and Future Outlook

12.10. Union Medico
12.10.1. Company Overview
12.10.2. Technology Overview
12.10.3. Product Portfolio
12.10.3.1. Autoinjectors: Product Details
12.10.3.1.1 Semi 45? Autoinjector
12.10.3.1.2 Semi 45?/ S Autoinjector
12.10.3.1.3 Semi 45?/ M Autoinjector
12.10.3.1.4 Semi 45?/ R Autoinjector
12.10.3.1.5 Comparison of 45? Autoinjectors
12.10.3.1.6 90?Autoinjector
12.10.3.1.7 90?/ S Autoinjector
12.10.3.1.8 90?/ M Autoinjector
12.10.3.1.9 90?/ XL Autoinjector
12.10.3.1.10 SuperGrip Autoinjector
12.10.3.1.11 Exclusive Autoinjector
12.10.3.1.12 Comparison of 90? Autoinjectors
12.10.4. Recent Developments and Future Outlook

12.11. Ypsomed
12.11.1. Company Overview
12.11.2. Financial Information
12.11.3. Product Portfolio
12.11.3.1. Autoinjectors: Product details
12.11.3.1.1. YpsoMate, YpsoMate Zero, YpsoMate 2.25 and YpsoMate 2.25Pro
12.11.3.1.2. VarioJect
12.11.3.1.3. LyoTwist Trio, LyoTwist Trio S, LyoTwist Vario and LyoTwist Vario S
12.11.3.1.4. Comparison of Autoinjectors
12.11.4. Collaborations
12.11.4.1. Royal Philips
12.11.4.2. Teva
12.11.5. Recent Developments and Future Outlook


13. EMERGING PLAYERS
13.1. Chapter Overview
13.2. AktiVax
13.3. Amneal Pharmaceuticals
13.4. kaléo
13.5. Nemera
13.6. Nuance Designs
13.7. Windgap Medical
13.8. Xeris Pharmaceuticals
13.9. Zion Clinical Pharmacy


14. KEY OPINION LEADERS (KOL) ANALYSIS
14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Principal Investigators Involved in Clinical Trials
14.3.1. Analysis by Type of Organization (KOL Affiliation)
14.3.2. Geographical Distribution of KOLs
14.4. Prominent KOLs
14.5. KOL Benchmarking: Roots Analysis' Assessment versus Third Party (ResearchGate Score)
14.6. Most Active KOLs
14.6.1. KOL Profile: A (Cedars-Sinai Medical Center)
14.6.2. KOL Profile: B (Mount Sinai Hospital)
14.6.3. KOL Profile: C (Magee-Womens Research Institute and Foundation)
14.6.4. KOL Profile: D (Imperial College London)
14.6.5. KOL Profile: E (Oslo University Hospital)

15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Autoinjectors: List of Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Most Active Players: Analysis by Number of Partnerships
15.3.4. Regional Analysis
15.3.4.1 Intercontinental and Intracontinental Agreements

16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Concluding Remarks


17. CASE STUDY: MEDICAL DEVICE CONTRACT SERVICE PROVIDERS
17.1. Chapter Overview
17.2. Challenges Associated with Medical Device Manufacturing
17.3. Role of CMOs in Medical Device Manufacturing
17.4. Services Offered by Medical Device CMOs
17.5. Advantages Offered by Medical Device CMOs
17.6. Risks Associated with Outsourcing to CMOs
17.7. Drug Delivery Device Service Providers
17.7.1. Analysis by Year of Establishment
17.7.2. Analysis by Company Size
17.7.3. Analysis by Geography
17.7.4. Analysis by Types of Services
17.8. Concluding Remarks

18. CASE STUDY: PREFILLED SYRINGES
18.1. Chapter Overview
18.2. Prefilled Syringes: List of Available / Under Development Devices
18.2.1. Analysis by Type of Barrel Fabrication Material
18.2.2. Analysis by Number of Barrel Chambers
18.2.3. Analysis by Type of Needle System
18.2.4. Analysis by Device Capacity
18.3. Prefilled Syringes: List of Developers
18.3.1. Analysis by Year of Establishment
18.3.2. Analysis by Company Size
18.3.3. Analysis by Geographical Location of Headquarters
18.3.4. Analysis by Geographical Location of Manufacturing Facilities
18.4. Technological Developments in Prefilled Syringes

19. MARKET SIZING AND OPPORTUNITY ANALYSIS
19.1. Chapter Overview
19.2. Forecast Methodology and Key Assumptions
19.3. Global Autoinjectors Market, 2021-2030 (By Value)
19.3.1. Global Autoinjectors Market: Distribution by Usability, 2021-2030 (By Value)
19.3.2. Global Autoinjectors Market: Distribution by Route of Administration, 2021- 2030 (By Value)
19.3.3. Global Autoinjectors Market: Distribution by Type of Molecule, 2021-2030 (By Value)
19.3.4. Autoinjectors Market in North America, 2021-2030 (By Value)
19.3.4.1. Autoinjectors Market in North America: Distribution by Usability, 2021-2030 (By Value)
19.3.4.2. Autoinjectors Market in North America: Distribution by Route of Administration, 2021-2030 (By Value)
19.3.4.3. Autoinjectors Market in North America: Distribution by Type of Molecule, 2021- 2030 (By Value)
19.3.5. Autoinjectors Market in Europe, 2021-2030 (By Value)
19.3.5.1. Autoinjectors Market in Europe: Distribution by Usability, 2021-2030 (By Value)
19.3.5.2. Autoinjectors Market in Europe: Distribution by Route of Administration, 2021- 2030 (By Value)
19.3.5.3. Autoinjectors Market in Europe: Distribution by Type of Molecule, 2021-2030 (By Value)
19.3.6. Autoinjectors Market in Asia Pacific, 2021-2030 (By Value)
19.3.6.1. Autoinjectors Market in Asia Pacific: Distribution by Usability, 2021-2030 (By Value)
19.3.6.2. Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Value)
19.3.6.3. Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2021- 2030 (By Value)
19.3.7. Autoinjectors Market in Rest of the World, 2021-2030 (By Value)
19.3.7.1. Autoinjectors Market in Rest of the World: Distribution by Usability, 20212030 (By Value)
19.3.7.2. Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Value)
19.3.7.3. Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Value)

19.4. Global Autoinjectors Market, 2021-2030 (By Volume)
19.4.1. Global Autoinjectors Market: Distribution by Usability, 2021-2030 (By Volume)
19.4.2. Global Autoinjectors Market: Distribution by Route of Administration, 2021- 2030 (By Volume)
19.4.3. Global Autoinjectors Market: Distribution by Type of Molecule, 2021-2030 (By Volume)
19.4.4. Autoinjectors Market in North America, 2021-2030 (By Volume)
19.3.4.1. Autoinjectors Market in North America: Distribution by Usability, 2021-2030 (By Volume)
19.3.4.2. Autoinjectors Market in North America: Distribution by Route of Administration, 2021-2030 (By Volume)
19.3.4.3. Autoinjectors Market in North America: Distribution by Type of Molecule, 2021- 2030 (By Volume)
19.3.5. Autoinjectors Market in Europe, 2021-2030 (By Volume)
19.3.5.1. Autoinjectors Market in Europe: Distribution by Usability, 2021-2030 (By Volume)
19.3.5.2. Autoinjectors Market in Europe: Distribution by Route of Administration, 2021- 2030 (By Volume)
19.3.5.3. Autoinjectors Market in Europe: Distribution by Type of Molecule, 2021-2030 (By Volume)
19.3.6. Autoinjectors Market in Asia Pacific, 2021-2030 (By Volume)
19.3.6.1. Autoinjectors Market in Asia Pacific: Distribution by Usability, 2021-2030 (By Volume)
19.3.6.2. Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Volume)
19.3.6.3. Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2021- 2030 (By Volume)
19.3.7. Autoinjectors Market in Rest of the World, 2021-2030 (By Volume)
19.3.7.1. Autoinjectors Market in Rest of the World: Distribution by Usability, 2021-2030 (By Volume)
19.3.7.2. Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Volume)
19.3.7.3. Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Volume)

19.5. Global Autoinjectors Market for Anaphylaxis, 2021-2030 (By Value)
19.5.1. Autoinjectors Market for Anaphylaxis in North America, 2021-2030 (By Value)
19.5.1.1. Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2021-2030 (By Value)
19.5.1.2. Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2021-2030 (By Value)
19.5.1.3. Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2021-2030 (By Value)
19.5.2. Autoinjectors Market for Anaphylaxis in Europe, 2021-2030 (By Value)
19.5.2.1. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2021- 2030 (By Value)
19.5.2.2. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2021-2030 (By Value)
19.5.2.3. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2021-2030 (By Value)
19.5.3. Autoinjectors Market for Anaphylaxis in Asia Pacific, 2021-2030 (By Value)
19.5.3.1. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2021-2030 (By Value)
19.5.3.2. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Value)
19.5.3.3. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Value)
19.5.4. Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2030 (By Value)
19.5.4.1. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2021-2030 (By Value)
19.5.4.2. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Value)
19.5.4.3. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Value)

19.6. Global Autoinjectors Market for Anaphylaxis, 2021-2030 (By Volume)
19.6.1. Autoinjectors Market for Anaphylaxis in North America, 2021-2030 (By Volume)
19.6.1.1. Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2021-2030 (By Volume)
19.6.1.2. Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2021-2030 (By Volume)
19.6.1.3. Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2021-2030 (By Volume)
19.6.2. Autoinjectors Market for Anaphylaxis in Europe, 2021-2030 (By Volume)
19.6.2.1. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2021- 2030 (By Volume)
19.6.2.2. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2021-2030 (By Volume)
19.6.2.3. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2021-2030 (By Volume)
19.6.3. Autoinjectors Market for Anaphylaxis in Asia Pacific, 2021-2030 (By Volume)
19.6.3.1. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2021-2030 (By Volume)
19.6.3.2. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Volume)
19.6.3.3. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Volume)
19.6.4. Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2030 (By Volume)
19.6.4.1. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2021-2030 (By Volume)
19.6.4.2. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Volume)
19.6.4.3. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Volume)

19.7. Global Autoinjectors Market for Multiple Sclerosis, 2021-2030 (By Value)
19.7.1. Autoinjectors Market for Multiple Sclerosis in North America, 2021-2030 (By Value)
19.7.1.1. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2021-2030 (By Value)
19.7.1.2. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2021-2030 (By Value)
19.7.1.3. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2021-2030 (By Value)
19.7.2. Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2030 (By Value)
19.7.2.1. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2021-2030 (By Value)
19.7.2.2. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2021-2030 (By Value)
19.7.2.3. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2021-2030 (By Value)
19.7.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2021-2030 (By Value)
19.7.3.1. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2021-2030 (By Value)
19.7.3.2. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Value)
19.7.3.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Value)
19.7.4. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2030 (By Value)
19.7.4.1. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2021-2030 (By Value)
19.7.4.2. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Value)
19.7.4.3. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Value)

19.8. Global Autoinjectors Market for Multiple Sclerosis, 2021-2030 (By Volume)
19.8.1. Autoinjectors Market for Multiple Sclerosis in North America, 2021-2030 (By Volume)
19.8.1.1. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2021-2030 (By Volume)
19.8.1.2. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2021-2030 (By Volume)
19.8.1.3. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2021-2030 (By Volume)
19.8.2. Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2030 (By Volume)
19.8.2.1. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2021-2030 (By Volume)
19.8.2.2. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2021-2030 (By Volume)
19.8.2.3. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2021-2030 (By Volume)
19.8.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2021-2030 (By Volume)
19.8.3.1. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2021-2030 (By Volume)
19.8.3.2. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Volume)
19.8.3.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Volume)
19.8.4. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2030 (By Volume)
19.8.4.1. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2021-2030 (By Volume)
19.8.4.2. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Volume)
19.8.4.3. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Volume)

19.9. Global Autoinjectors Market for Rheumatoid Arthritis, 2021-2030 (By Value)
19.9.1. Autoinjectors Market for Rheumatoid Arthritis in North America, 2021-2030 (By Value)
19.9.1.1. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2021-2030 (By Value)
19.9.1.2. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2021-2030 (By Value)
19.9.1.3. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2021-2030 (By Value)
19.9.2. Autoinjectors Market for Rheumatoid Arthritis in Europe, 2021-2030 (By Value)
19.9.2.1. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2021-2030 (By Value)
19.9.2.2. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2021-2030 (By Value)
19.9.2.3. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2021-2030 (By Value)
19.9.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2021-2030 (By Value)
19.9.3.1. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2021-2030 (By Value)
19.9.3.2. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Value)
19.9.3.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Value)
19.9.4. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2021-2030 (By Value)
19.9.4.1. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2021-2030 (By Value)
19.9.4.2. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Value)
19.9.4.3. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Value)

19.10. Global Autoinjectors Market for Rheumatoid Arthritis, 2021-2030 (By Volume)
19.10.1. Autoinjectors Market for Rheumatoid Arthritis in North America, 2021-2030 (By Volume)
19.10.1.1. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2021-2030 (By Volume)
19.10.1.2. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2021-2030 (By Volume)
19.10.1.3. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2021-2030 (By Volume)
19.10.2. Autoinjectors Market for Rheumatoid Arthritis in Europe, 2021-2030 (By Volume)
19.10.2.1. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2021-2030 (By Volume)
19.10.2.2. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2021-2030 (By Volume)
19.10.2.3. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2021-2030 (By Volume)
19.10.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2021-2030 (By Volume)
19.10.3.1. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2021-2030 (By Volume)
19.10.3.2. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Volume)
19.10.3.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Volume)
19.10.4. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2021-2030 (By Volume)
19.10.4.1. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2021-2030 (By Volume)
19.10.4.2. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Volume)
19.10.4.3. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Volume)

19.11. Global Autoinjectors Market for Migraine, 2021-2030 (By Value)
19.11.1. Autoinjectors Market for Migraine in North America, 2021-2030 (By Value)
19.11.1.1. Autoinjectors Market for Migraine in North America: Distribution by Usability, 2021-2030 (By Value)
19.11.1.2. Autoinjectors Market for Migraine in North America: Dist

List of Figures
Figure 3.1 Popular Drug Delivery Systems
Figure 3.2 Types of Self-Injection Devices
Figure 3.3 Components of an Autoinjector
Figure 3.4 Cartridge Based Autoinjectors versus Prefilled Syringe Based Autoinjectors
Figure 3.5 Classification of Autoinjectors
Figure 5.1 Autoinjectors: Distribution by Usability

Please contact our Customer Support Center to get the complete Table of Contents